Advanced search×

Academic medical centers and conflicts of interest.

Orin M Goldblum and Michael J Franzblau

JAMA 295(24):2845-6; author reply 2848-9 (2006) PMID 16804142

DOI: 10.1001/jama.295.24.2845-c
Version: za2963e q8za6 q8zbf q8zcf q8zdc q8ze3 q8zf2 q8zgd
Buy PDF

Similar articles you may find interesting…

  1. Real-life effectiveness and tolerability of rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: The EMBRAC...
    Serge Gauthier, Alain Robillard, and on behalf of the EMBRACE investigators

    Curr Med Res Opin (2013) PMID 23647369

    Rivastigmine transdermal patch is effective in maintaining cognitive function over 18 months of treatment in patients with mild-to-moderate AD. The safety profile was comparable to the data in the Canadian product monograph. Lack of a comparator group is a potential limitation of the study....
    Buy PDF
  2. From F=ma to Flying Squirrels: Curricular Change in an Introductory Physics Course
    Brian W O'Shea, Laura Terry, and Walter Benenson

    arXiv:1305.1398 [physics.ed-ph] 7 May 2013

    We present outcomes from curricular changes made to an introductory Calculus-based physics course whose audience is primarily life science majors, The majority of whom plan to pursue post-baccalaureate studies in medical and Scientific fields. During the 2011-12 academic year, we implemented a "Phys...
    View PDF
  3. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for r...
    Mark Cascione, Daniel Wynn, and Kevin McCague

    J Med Econ (2013) PMID 23647445

    Results of the EPOC study are anticipated in early 2013 and will inform treatment selection by providing patient-centered data on therapy switch to fingolimod or standard-of-care DMTs. Trial Registration: ClinicalTrials.gov NCT01216072....
    Buy PDF